A Phase 3 interventional study of Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ) and MenACWY-CRM conjugate vaccine in N. Meningitidis Carriage, sponsored by Novartis Vaccines. Completed at 10 sites in United Kingdom. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-21.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal vaccines on carriage of Neisseria meningitidis in a young adult population.
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
First submitted before Novartis Vaccines left Novartis.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
Biological: Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)
Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
Biological: MenACWY-CRM conjugate vaccine
Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
Biological: Japanese Encephalitis vaccine
Also known as: IXIARO
Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination
Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported. Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.
Time frame: 61 days (31 days after receiving the second injection)
Percentages of Subjects With Combined Carriage of N. Meningitidis Serogroups A, C, W and Y, One Month After MenACWY-CRM Vaccination
The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
Time frame: 31 days after MenACWY-CRM injection
Percentages of Subjects With Carriage of All ST Types of N. Meningitidis B (Genogroupable) at Different Time Points Following rMenB+OMV NZ Vaccination
The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of Virulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination
Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of Nonvirulent ST Types of N. Meningitidis Group B at Any Time Point After rMenB+OMV NZ Vaccination
Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of All N.Meningitidis Strain at Different Time Points After rMenB+OMV NZ Vaccination
Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N.Meningitidis ABCWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N.Meningitidis ACWY Genogroups at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N.Meningitidis Serogroups A,C,W or Y at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N.Meningitidis Genogroup Y at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N.Meningitidis Serogroup Y at Different Time Points After rMenB+OMV NZ Vaccination
Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subject With Carriage of N. Meningitidis Genogroups ACWY at Different Time Points After MenACWY-CRM Vaccination
Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N. Meningitidis Serogroups ACWY at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N. Meningitidis Genogroup Y at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With Carriage of N. Meningitidis Serogroup Y at Different Time Points After MenACWY-CRM Vaccination
Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination
The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of Virulent ST Types of N. Meningitidis Genogroup B at Different Time Points Following rMenB+OMV NZ Vaccination
The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of All N. Meningitidis at Different Time Points Following rMenB+OMV NZ Vaccination
The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Genogroups ABCWY at Different Time Points Following rMenB+OMV NZ Vaccination
The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroups ACWY at Different Time-points After MenACWY-CRM Vaccination
The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With New Acquisition of Pharyngeal Carriage of N. Meningitidis Serogroup Y at Different Time-points After MenACWY-CRM Vaccination
The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.
Time frame: Up to 361 days after vaccination
The Duration of Any Carriage of N.Meningitidis Strains After Vaccination With rMenB+OMV
The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.
Time frame: Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)
The Duration of Carriage of Any N. Meningitidis Strain After Vaccination With MenACWY-CRM
The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.
Time frame: Any time post vaccination (the date of first observation of the carriage and the date of the last observation of the carriage)
The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With rMenB+OMV Vaccine
The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.
Time frame: Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)
The Duration of Carriage After New Acquisition N.Meningitidis Strains Following Vaccination With MenACWY Vaccine
The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.
Time frame: Any post vaccination timepoint (the date of first observation of the carriage and the date of the last observation of the carriage)
Percentages of Subjects With N. Meningitidis Carriage of Virulent ST of Group B, Stratified by Pre-vaccination hSBA Titer After rMenB+OMV NZ Vaccination
The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported. The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA). H44/76, 5/99 and NZ98/254 are strains in serogroup B.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With N. Meningitidis Carriage of Serogroup Y After MenACWY-CRM Vaccination, Stratified by Pre-vaccination hSBA Titers
The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.
Time frame: Up to 12 months after vaccination
Percentages of Subjects With hSBA Titers ≥1:4 Against N. Meningitidis Serogroup B After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group
The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
Time frame: Up to 361 days after vaccination
The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup B, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.
The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With hSBA Titers ≥1:8 Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.
The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.
Time frame: Up to 361 days after vaccination
The hSBA Geometric Mean Titers Against N. Meningitidis Serogroup C and Y, After rMenB+OMV NZ or MenACWY-CRM Vaccination Compared to Control Group.
The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs. Serogroups A and W were not analysed.
Time frame: Up to 361 days after vaccination
Percentages of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups C and Y After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group.
The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported. Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer \< 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer. Analysis was not done for serogroups A and W.
Time frame: 61 days
The hSBA Geometric Mean Titers Against N. Meningitidis Serogroups C and Y in Subjects (Who Have Received a Prior Dose of MenC Vaccine) After Vaccination With MenACWY-CRM in This Study Compared to Control Group
The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. Analysis was not done for serogroups A and W.
Time frame: Up to 361 days after vaccination
Percentages of Subjects (Who Have Received a Prior Dose of MenC Vaccine) With hSBA Titers ≥1:8 Against N. Meningitidis Serogroups C and Y After Vaccination With MenACWY-CRM in This Study Compared to Control Group.
The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported. Analysis was not done for serogroups A and W.
Time frame: Up to 361 days after vaccination
Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination With rMenB+OMV NZ or MenACWY-CRM Compared to Control Group
The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.
Time frame: Day 1 through day 7 after any vaccination
Subjects were enrolled from 10 sites in United Kingdom
| Milestone | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Started | 979 | 988 | 987 |
| Completed | 796 | 844 | 826 |
| Not completed | 183 | 144 | 161 |
| Withdrew: Withdrawal by subject | 38 | 31 | 28 |
| Withdrew: Lost to follow-up | 124 | 98 | 123 |
| Withdrew: Protocol violation | 5 | 5 | 6 |
| Withdrew: Adverse event or death | 11 | 8 | 3 |
| Withdrew: Inappropriate enrollment | 2 | 1 | 0 |
| Withdrew: Administrative reason | 1 | 0 | 0 |
| Withdrew: Unable to classify | 2 | 1 | 1 |
Percentages of subjects with carriage of virulent sequence types (ST) of Neisseria meningitidis group B, one month after completion of rMenB+OMV NZ vaccination. The carriage rate of virulent sequence types (ST) of N. meningitidis group B (genogroupable) in subjects, one month after receiving two doses of rMenB+OMV NZ, as compared to the control group, was reported. Virulent ST types are defined as Clonal Complex multi locus sequence typing (MLST) or ST type being the same compared to history data (Clonal Complexes MLST or ST types found to be virulent and causing diseases) from the years 2006 to 2010.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 8 (6 to 10) | 7 (6 to 9) |
| Month 2 (N= 916, 928) | 9 (8 to 12) | 8 (6 to 10) |
The percentage of subjects with combined carriage rate of N. meningitidis serogroups A, C, W and Y in subjects, one month after receiving a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline | 6 (5 to 8) | 5 (4 to 7) |
| Month 1 (N=956, 947) | 6 (5 to 8) | 6 (5 to 8) |
The percentage of subjects with carriage of all (virulent + non-virulent) ST types of N. meningitidis B (genogroupable) in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 9 (8 to 11) | 9 (7 to 11) |
| 1 month post 1st vaccination (Day 31) N=931, 947 | 9 (7 to 11) | 9 (7 to 11) |
| 1 month post 2nd vaccination (Day 61) N=916, 928 | 11 (9 to 13) | 10 (8 to 12) |
| 3 months post 2nd vaccination (Day 121) N=860, 885 | 10 (8 to 12) | 10 (8 to 12) |
| 5 months post 2nd vaccination (Day 181) N=832, 864 | 9 (8 to 12) | 10 (8 to 12) |
| 11 months post 2nd vaccination (Day 361) N=797,827 | 8 (6 to 10) | 10 (8 to 12) |
Percentage of subjects with carriage of virulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 8 (6 to 10) | 7 (6 to 9) |
| 1 month post 1st vaccination (Day 31) N=931,947 | 8 (6 to 10) | 8 (6 to 10) |
| 1 month post 2nd vaccination (Day 61) N=916, 928 | 9 (8 to 12) | 8 (6 to 10) |
| 3 months post 2nd vaccination (Day 121) N=860, 885 | 9 (7 to 11) | 9 (8 to 11) |
| 5 months post 2nd vaccination (Day 181) N=832,864 | 9 (7 to 11) | 9 (7 to 11) |
| 11 months post 2nd vaccination (Day 361) N=797,827 | 8 (6 to 10) | 9 (7 to 11) |
Percentage of subjects with carriage of nonvirulent ST types of N. meningitidis group B (genogroupable) in subjects at different time points of the study point after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 1 (1 to 2) | 1 (1 to 2) |
| 1 month post 1st vaccination (N=931,947) | 1 (0 to 2) | 1 (0 to 2) |
| 1 month post 2nd vaccination (N=916,928) | 1 (1 to 2) | 2 (1 to 3) |
| 3 months post 2nd vaccination (N=860,885) | 1 (0 to 2) | 1 (0 to 2) |
| 5 months post 2nd vaccination (N=832,864) | 1 (0 to 2) | 1 (0 to 2) |
| 11 months post 2nd vaccination (N=797,827) | 1 (0 to 1) | 1 (0 to 2) |
Percentage of subjects with carriage of all N.meningitidis strains combined in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 33 (31 to 37) | 31 (28 to 34) |
| 1 month post 1st vaccination (N=931, 947) | 34 (31 to 37) | 32 (29 to 35) |
| 1 month post 2nd vaccination (N=916, 928) | 38 (35 to 41) | 36 (33 to 40) |
| 3 months post 2nd vaccination (N=860, 885) | 35 (32 to 39) | 36 (33 to 39) |
| 5 months post 2nd vaccination (N=832, 864) | 34 (30 to 37) | 36 (33 to 40) |
| 11 months post 2nd vaccination (N=797, 827) | 27 (24 to 30) | 30 (27 to 34) |
Percentages of subjects with carriage of N.meningitidis ABCWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 19 (17 to 22) | 17 (15 to 19) |
| 1 month post 1st vaccination (N=931, 947) | 19 (17 to 22) | 19 (16 to 21) |
| 1 month post 2nd vaccination (N=916, 928) | 22 (19 to 25) | 22 (19 to 24) |
| 3 months post 2nd vaccination (N=860, 885) | 20 (17 to 23) | 22 (19 to 25) |
| 5 months post 2nd vaccination (N=832, 864) | 19 (17 to 22) | 23 (20 to 26) |
| 11 months post 2nd vaccination (N=797, 827) | 15 (12 to 17) | 18 (15 to 20) |
Percentages of subjects with carriage of N.meningitidis ACWY genogroups in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 10 (8 to 12) | 8 (7 to 10) |
| 1 month post 1st vaccination (N=931, 947) | 11 (9 to 13) | 10 (8 to 12) |
| 1 month post 2nd vaccination (N=916, 928) | 11 (9 to 13) | 12 (10 to 14) |
| 3 months post 2nd vaccination (N=860, 885) | 10 (8 to 12) | 12 (10 to 14) |
| 5 months post 2nd vaccination (N=832, 864) | 10 (8 to 12) | 13 (11 to 15) |
| 11 months post 2nd vaccination (N=797, 827) | 7 (5 to 8) | 8 (6 to 10) |
Percentages of subjects with carriage of N.meningitidis serogroups A,C,W or Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 7 (6 to 9) | 5 (4 to 7) |
| 1 month post 1st vaccination (N=931, 947) | 7 (5 to 9) | 6 (5 to 8) |
| 1 month post 2nd vaccination (N=916, 928) | 7 (5 to 9) | 8 (6 to 10) |
| 3 months post 2nd vaccination (N=860, 885) | 6 (5 to 8) | 8 (6 to 10) |
| 5 months post 2nd vaccination (N=832, 864) | 6 (5 to 8) | 9 (7 to 11) |
| 11 months post 2nd vaccination (N=797, 827) | 5 (4 to 7) | 5 (3 to 7) |
Percentages of subjects with carriage of N.meningitidis genogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 7 (6 to 9) | 7 (5 to 9) |
| 1 month post 1st vaccination (N=931, 947) | 9 (7 to 11) | 8 (7 to 10) |
| 1 month post 2nd vaccination (N=916, 928) | 9 (7 to 11) | 10 (9 to 13) |
| 3 months post 2nd vaccination (N=860, 885) | 8 (6 to 10) | 10 (8 to 12) |
| 5 months post 2nd vaccination (N=832, 864) | 8 (7 to 10) | 10 (8 to 13) |
| 11 months post 2nd vaccination (N=797, 827) | 5 (4 to 7) | 6 (5 to 8) |
Percentages of subjects with carriage of N.meningitidis serogroup Y in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline | 6 (4 to 7) | 5 (3 to 6) |
| 1 month post 1st vaccination (N=931, 947) | 6 (4 to 8) | 5 (4 to 7) |
| 1 month post 2nd vaccination (N=916, 928) | 5 (4 to 7) | 7 (6 to 9) |
| 3 months post 2nd vaccination (N=860, 885) | 5 (4 to 7) | 7 (5 to 9) |
| 5 months post 2nd vaccination (N=832, 864) | 6 (4 to 8) | 7 (6 to 9) |
| 11 months post 2nd vaccination (N=797, 827) | 4 (3 to 6) | 4 (3 to 6) |
Percentages of subject with carriage of N. meningitidis genogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline | 9 (7 to 11) | 8 (7 to 10) |
| 1 month post 1 dose (N=956, 947) | 10 (8 to 12) | 10 (8 to 12) |
| 2 months post 1 dose (N=929, 928) | 9 (8 to 12) | 12 (10 to 14) |
| 4 months post 1 dose (N=884, 885) | 10 (8 to 12) | 12 (10 to 14) |
| 6 months post 1 dose (N=867, 864) | 11 (9 to 13) | 13 (11 to 15) |
| 12 months post 1 dose (N=845, 827) | 8 (6 to 10) | 8 (6 to 10) |
Percentages of subjects with carriage of N. meningitidis serogroups ACWY in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline (Day 1) | 6 (5 to 8) | 5 (4 to 7) |
| 1 month post 1 dose (N=956, 947) | 6 (5 to 8) | 6 (5 to 8) |
| 2 months post 1 dose (N=929, 928) | 5 (4 to 7) | 8 (6 to 10) |
| 4 months post 1 dose (N=884, 885) | 6 (5 to 8) | 8 (6 to 10) |
| 6 months post 1 dose (N=867, 864) | 6 (5 to 8) | 9 (7 to 11) |
| 12 months post 1 dose (N=845, 827) | 4 (3 to 6) | 5 (3 to 7) |
Percentages of subjects with carriage of N. meningitidis genogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline | 7 (5 to 8) | 7 (5 to 9) |
| 1 month post 1 dose (N=956, 947) | 7 (6 to 9) | 8 (7 to 10) |
| 2 months post 1 dose (N=929, 928) | 7 (6 to 9) | 10 (9 to 13) |
| 4 months post 1 dose (N=884, 885) | 8 (6 to 10) | 10 (8 to 12) |
| 6 months post 1 dose (N=867, 864) | 9 (7 to 11) | 10 (8 to 13) |
| 12 months post 1 dose (N=845, 827) | 6 (5 to 8) | 6 (5 to 8) |
Percentages of subjects with carriage of N. meningitidis serogroup Y in subjects at different time points of the study after administration of a single dose of MenACWY-CRM conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline | 4 (3 to 6) | 5 (3 to 6) |
| 1 month post 1 dose (N=956, 947) | 5 (4 to 6) | 5 (4 to 7) |
| 2 months post 1 dose (N=929, 928) | 4 (3 to 5) | 7 (6 to 9) |
| 4 months post 1 dose (N=884, 885) | 5 (4 to 7) | 7 (5 to 9) |
| 6 months post 1 dose (N=867, 864) | 5 (4 to 7) | 7 (6 to 9) |
| 12 months post 1 dose (N=845, 827) | 4 (3 to 5) | 4 (3 to 6) |
The percentages of subjects with newly acquired pharyngeal carriage of all ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline non-carrier | 90 (87 to 92) | 91 (89 to 93) |
| 1 month post 1st vaccination (N=671, 715) | 3 (2 to 5) | 4 (2 to 5) |
| 1 month post 2nd vaccination (N=650, 687) | 3 (2 to 5) | 2 (1 to 3) |
| 3 months post 2nd vaccination (N=628, 674) | 1 (0 to 2) | 3 (1 to 4) |
| 5 months post 2nd vaccination (N=623, 656) | 1 (1 to 3) | 2 (1 to 4) |
| 11 months post 2nd vaccination (N=614, 642) | 3 (2 to 5) | 3 (2 to 5) |
| At 3,5,11 months post 2nd vaccination (N=628,674) | 5 (4 to 7) | 7 (6 to 10) |
The percentages of subjects with newly acquired pharyngeal carriage of virulent ST types of N. meningitidis genogroup B in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline non-carrier | 91 (89 to 93) | 92 (90 to 94) |
| 1 month post 1st vaccination (N=682, 726) | 3 (2 to 5) | 3 (2 to 5) |
| 1 month post 2nd vaccination (N=659, 699) | 3 (2 to 5) | 2 (1 to 3) |
| 3 months post 2nd vaccination (N=638, 686) | 1 (0 to 2) | 2 (1 to 4) |
| 5 months post 2nd vaccination (N=632, 670) | 1 (1 to 3) | 2 (1 to 3) |
| 11 months post 2nd vaccination (N=623, 656) | 3 (2 to 5) | 2 (1 to 4) |
| At 3,5, 11 months post 2nd vaccination (N=638,686) | 5 (4 to 7) | 6 (5 to 9) |
The percentages of subjects with newly acquired pharyngeal carriage of all N. meningitidis in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline non-carrier | 77 (74 to 80) | 80 (77 to 83) |
| 1 month post 1st vaccination (N=578, 627) | 17 (14 to 20) | 18 (15 to 21) |
| 1 month post 2nd vaccination (N=479, 513) | 14 (11 to 18) | 12 (9 to 15) |
| 3 months post 2nd vaccination (N=410, 452) | 9 (6 to 12) | 13 (10 to 16) |
| 5 months post 2nd vaccination (N=374, 395) | 8 (5 to 11) | 9 (6 to 12) |
| 11 months post 2nd vaccination (N=344, 361) | 11 (8 to 15) | 14 (10 to 18) |
| At 3,5, 11 months post 2nd vaccination (N=410,452) | 26 (21 to 30) | 31 (27 to 35) |
The percentages of subjects with newly acquired pharyngeal carriage of N. meningitidis genogroups ABCWY in subjects at different time points of the study after administration of two doses of rMenB+OMV NZ conjugate vaccine as compared to the control group is reported.
| Percentages of subjects | rMenB+OMV | Control |
|---|---|---|
| Baseline non-carrier | 82 (79 to 85) | 84 (82 to 87) |
| 1 month post 1st vaccination (N=611, 663) | 9 (7 to 12) | 10 (8 to 13) |
| 1 month post 2nd vaccination (N=553, 592) | 6 (4 to 8) | 7 (5 to 9) |
| 3 months post 2nd vaccination (N=519, 551) | 4 (3 to 6) | 7 (5 to 9) |
| 5 months post 2nd vaccination (N=497, 515) | 5 (3 to 7) | 5 (3 to 7) |
| 11 months post 2nd vaccination (N=472, 491) | 6 (4 to 8) | 6 (4 to 9) |
| At 3,5, 11 months post 2nd vaccination (N=519,551) | 14 (11 to 18) | 17 (14 to 20) |
The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroups A,C, W or Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline non-carrier | 94 (92 to 96) | 95 (93 to 96) |
| 1 month post 1st vaccination (N=746, 745) | 4 (3 to 6) | 5 (3 to 6) |
| 1 month post 2nd vaccination (N=712, 709) | 2 (1 to 3) | 4 (3 to 6) |
| 3 months post 2nd vaccination (N=701, 680) | 2 (1 to 4) | 3 (2 to 5) |
| 5 months post 2nd vaccination (N=685, 660) | 3 (2 to 4) | 2 (1 to 3) |
| 11 months post 2nd vaccination (N=666, 650) | 2 (1 to 3) | 1 (1 to 3) |
| 1,3,5, 11 months post 2nd vaccination (N=712, 709) | 8 (6 to 11) | 10 (8 to 12) |
The percentages of subjects with newly acquired pharyngeal carriage of N.meningitidis serogroup Y at different time-points in the study after MenACWY-CRM vaccination as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline non-carrier | 95 (94 to 97) | 95 (94 to 97) |
| 1 month post 1st vaccination (N=758, 749) | 4 (2 to 5) | 4 (3 to 6) |
| 1 month post 2nd vaccination (N=730, 719) | 1 (1 to 2) | 4 (2 to 5) |
| 3 months post 2nd vaccination (N=719, 693) | 1 (1 to 3) | 2 (1 to 4) |
| 5 months post 2nd vaccination (N=709, 678) | 2 (1 to 3) | 1 (1 to 3) |
| 11 months post 2nd vaccination (N=694, 669) | 2 (1 to 3) | 1 (1 to 3) |
| 1,3,5, 11 months post 2nd vaccination (N=730, 719) | 6 (5 to 8) | 8 (6 to 10) |
The duration of carriage of any N.meningitidis strains after receiving two doses of rMenB+OMV compared to that in the control group is reported.
| Number of days | rMenB+OMV | Control |
|---|---|---|
| Genogroup B All STs (N=152, 160) | 127 (92 to 162) | 146 (112 to 180) |
| Genogroup B virulent STs (N=142, 142) | 122 (87 to 157) | 147 (113 to 182) |
| All N meningitidis | 193 (176 to 210) | 202 (185 to 219) |
| Genogroups ABCWY (N=300, 323) | 143 (122 to 164) | 162 (141 to 183) |
| Serogroups ACWY (N=131, 142) | 104 (79 to 129) | 113 (87 to 138) |
| Serogroup Y (N=106, 123) | 106 (79 to 132) | 117 (91 to 144) |
The duration of carriage of any N meningitidis strain after receiving one dose MenACWY-CRM as compared to that in control group is reported.
| Number of days | MenACWY | Control |
|---|---|---|
| Serogroups ACWY | 88 (62 to 114) | 113 (87 to 138) |
| Serogroup Y (N=110, 123) | 86 (59 to 114) | 117 (91 to 144) |
The duration of carriage after new acquisition of N.meningitidis strains after receiving two doses of rMenB+OMV vaccine compared to that in the control group is reported.
| Number of days | rMenB+OMV | Control |
|---|---|---|
| Genogroup B All STs (N=76, 89) | 82 (44 to 120) | 107 (71 to 142) |
| Genogroup B virulent STs (N=77, 82) | 80 (42 to 117) | 107 (70 to 143) |
| All N meningitidis | 158 (135 to 181) | 165 (142 to 188) |
| Genogroups ABCWY (N=165, 201) | 121 (96 to 146) | 146 (122 to 170) |
| Serogroups ACWY (N=75, 102) | 111 (79 to 143) | 120 (89 to 151) |
| Serogroup Y (N=61, 87) | 111 (76 to 146) | 120 (87 to 153) |
The duration of carriage after new acquisition of N.meningitidis strains after receiving one dose of MenACWY-CRM vaccine compared to that in the control group is reported.
| Number of days | MenACWY | Control |
|---|---|---|
| Serogroups ACWY | 90 (57 to 123) | 120 (89 to 151) |
| Serogroup Y (N=74, 87) | 87 (52 to 122) | 120 (87 to 153) |
The percentages of subjects with N. meningitidis Virulent ST of serogroup B, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<4 and ≥4) titers after administration of two doses of rMenB+OMV NZ vaccine as compared to the control group is reported. The serum bactericidal antibodies directed against N.meningitides serogroups, are measured by Serum Bactericidal Assay using human complement (hSBA). H44/76, 5/99 and NZ98/254 are strains in serogroup B.
| Percentage | rMenB+OMV | Control |
|---|---|---|
| Baseline hSBA < 4 (H44/76) (N=60,19) | 0 (0 to 6) | 0 (0 to 18) |
| 1month post 1st dose; hSBA<4(H44/76) (N=60, 18) | 3 (0 to 12) | 0 (0 to 19) |
| 1month post 2nd dose; hSBA<4(H44/76) (N=60, 18) | 7 (2 to 16) | 0 (0 to 19) |
| 3months post 2nd dose; hSBA<4(H44/76) (N=56, 17) | 4 (0 to 12) | 0 (0 to 20) |
| 5 months post 2nd dose; hSBA <4(H44/76) (N=56, 17) | 7 (2 to 17) | 0 (0 to 20) |
| 11 months post 2nd dose;hSBA <4(H44/76) (N=56, 16) | 11 (4 to 22) | 0 (0 to 21) |
| Baseline hSBA ≥4 (H44/76) | 10 (5 to 16) | 6 (1 to 21) |
| 1month post 1st dose; hSBA ≥4 (H44/76) (N=130, 30) | 5 (2 to 11) | 10 (2 to 27) |
| 1 month post 2nd dose;hSBA ≥4 (H44/76) (N=130, 30) | 8 (4 to 14) | 7 (1 to 22) |
| 3 months post 2nd dose;hSBA ≥4 (H44/76) (N=120,29) | 9 (5 to 16) | 14 (4 to 32) |
| 5 months post 2nd dose;hSBA ≥4 (H44/76) (N=115,28) | 5 (2 to 11) | 11 (2 to 28) |
| 11 months post 2nd dose;hSBA ≥4 (H44/76)(N=123,30) | 5 (2 to 10) | 7 (1 to 22) |
| Baseline hSBA < 4 (5/99) (N=77, 23) | 5 (1 to 13) | 9 (1 to 28) |
| 1month post 1st dose; hSBA<4 (5/99) (N=77, 22) | 4 (1 to 11) | 9 (1 to 29) |
| 1 month post 2nd dose;hSBA <4 (5/99) (N=77, 22) | 6 (2 to 15) | 0 (0 to 15) |
| 3 months post 2nd dose;hSBA <4 (5/99) (N=71, 21) | 4 (1 to 12) | 10 (1 to 30) |
| 5 months post 2nd dose;hSBA <4 (5/99) (N=68, 21) | 3 (0 to 10) | 10 (1 to 30) |
| 11 months post 2nd dose;hSBA <4(5/99) (N=71, 20) | 7 (2 to 16) | 5 (0 to 25) |
| Baseline hSBA ≥4 (5/99) (N=116, 27) | 8 (4 to 14) | 0 (0 to 13) |
| 1month post 1st dose; hSBA ≥4 (5/99) (N=113, 26) | 5 (2 to 11) | 4 (0.097 to 20) |
| 1 month post 2nd dose;hSBA ≥4 (5/99) (N=113, 26) | 8 (4 to 15) | 8 (1 to 25) |
| 3 months post 2nd dose;hSBA ≥4 (5/99) (N=105, 25) | 10 (5 to 17) | 8 (1 to 26) |
| 5 months post 2nd dose;hSBA ≥4 (5/99) (N=103, 24) | 8 (3 to 15) | 4 (0 to 21) |
| 11 months post 2nd dose;hSBA ≥4(5/99) (N=108, 26) | 6 (3 to 13) | 4 (0.097 to 20) |
| Baseline hSBA < 4 (NZ98/254) (N=83, 31) | 2 (0 to 8) | 6 (1 to 21) |
| 1month post 1st dose; hSBA<4(NZ98/254) (N=81, 30) | 4 (1 to 10) | 7 (1 to 22) |
| 1month post 2nd dose; hSBA<4 (NZ98/254) (N=81, 30) | 4 (1 to 10) | 0 (0 to 12) |
| 3 months post 2nd dose;hSBA <4 (NZ98/254)(N=75,29) | 3 (0 to 9) | 3 (0.087 to 18) |
| 5 months post 2nd dose;hSBA <4 (NZ98/254)(N=70,29) | 3 (0 to 10) | 3 (0.087 to 18) |
| 11 months post 2nd dose;hSBA <4(NZ98/254)(N=75,28) | 11 (5 to 20) | 4 (0.09 to 18) |
| Baseline hSBA ≥4 (NZ98/254) (N=110, 19) | 10 (5 to 17) | 0 (0 to 18) |
| 1month post 1st dose; hSBA ≥4 (NZ98/254)(N=109,18) | 6 (2 to 12) | 6 (0 to 27) |
| 1 month post 2nd dose;hSBA ≥4 (NZ98/254)(N=109,18) | 10 (5 to 17) | 11 (1 to 35) |
| 3 months post 2nd dose;hSBA ≥4(NZ98/254)(N=101,17) | 11 (6 to 19) | 18 (4 to 43) |
| 5 months post 2nd dose;hSBA ≥4(NZ98/254)(N=101,16) | 8 (3 to 15) | 13 (2 to 38) |
| 11 months post 2nd dose;hSBA≥4(NZ98/254)(N=104,18) | 4 (1 to 10) | 6 (0 to 27) |
The prevalence of carriage of N. meningitidis serogroup Y, at different time points of the study, in subjects stratified by pre-vaccination hSBA (\<8 and ≥8) titers, after administration of one dose of MenACWY-CRM vaccine as compared to the control group is reported.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline hSBA <8 (MenY) (N=42, 44) | 0 (0 to 8) | 0 (0 to 8) |
| 1month post 1st dose; hSBA <8 (MenY) (N=39, 40) | 0 (0 to 9) | 3 (0.063 to 13) |
| 1 month post 2nd dose;hSBA <8 (MenY) (N=39, 40) | 0 (0 to 9) | 0 (0 to 9) |
| 3 months post 2nd dose;hSBA <8 (MenY) (N=36, 37) | 0 (0 to 10) | 3 (0.068 to 14) |
| 5 months post 2nd dose;hSBA <8 (MenY) (N=36, 36) | 0 (0 to 10) | 6 (1 to 19) |
| 11 months post 2nd dose;hSBA <8 (MenY) (N=34, 35) | 3 (0.074 to 15) | 6 (1 to 19) |
| Baseline hSBA ≥8 (MenY) | 6 (3 to 11) | 6 (3 to 11) |
| 1month post 1st dose; hSBA ≥8 (MenY) (N=146,151) | 6 (3 to 11) | 5 (2 to 10) |
| 1 month post 2nd dose;hSBA ≥8 (MenY) (N=143, 149) | 5 (2 to 10) | 5 (2 to 10) |
| 3 months post 2nd dose;hSBA ≥8 (MenY) (N=131, 139) | 8 (4 to 14) | 7 (4 to 13) |
| 5 months post 2nd dose;hSBA ≥8 (MenY) (N=130, 134) | 9 (5 to 16) | 5 (2 to 10) |
| 11 months post 2nd dose;hSBA ≥8 (MenY) (N=129,135) | 4 (1 to 9) | 3 (1 to 7) |
The percentages of subjects with hSBA titers ≥1:4 against the three strains of N. meningitidis B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
| Percentages of subjects | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Baseline H44/76 | 69 (62 to 75) | 71 (57 to 83) | 62 (47 to 75) |
| 1 month post 2nd dose (H44/76) (N=189, 45, 48) | 100 (98 to 100) | 76 (60 to 87) | 63 (47 to 76) |
| 3 months post 2nd dose (H44/76) (N=173, 40, 46) | 99 (97 to 100) | 73 (56 to 85) | 65 (50 to 79) |
| 5 months post 2nd dose (H44/76) (N=169, 43, 45) | 100 (98 to 100) | 74 (59 to 86) | 67 (51 to 80) |
| 11 months post 2nd dose (H44/76) (N=177, 41, 46) | 95 (91 to 98) | 76 (60 to 88) | 70 (54 to 82) |
| Baseline 5/99 | 60 (53 to 67) | 45 (31 to 60) | 54 (39 to 68) |
| 1 month post 2nd dose (5/99) (N=189, 45, 48) | 100 (98 to 100) | 40 (26 to 56) | 58 (43 to 72) |
| 3 months post 2nd dose (5/99) (N=173, 40, 46) | 99 (97 to 100) | 49 (33 to 65) | 53 (38 to 68) |
| 5 months post 2nd dose (5/99) (N=169, 43, 45) | 99 (97 to 100) | 49 (33 to 65) | 53 (38 to 68) |
| 11 months post 2nd dose (5/99) (N=177, 41, 46) | 97 (94 to 99) | 51 (35 to 67) | 63 (48 to 77) |
| Baseline NZ98/254 | 57 (50 to 64) | 53 (38 to 67) | 38 (25 to 53) |
| 1 month post 2nd dose (NZ98/254) (N=189, 45, 48) | 99 (97 to 100) | 53 (38 to 68) | 44 (29 to 59) |
| 3 months post 2nd dose (NZ98/254) (N=173, 40, 46) | 93 (88 to 96) | 48 (32 to 64) | 48 (33 to 63) |
| 5 months post 2nd dose (NZ98/254) (N=169, 43, 45) | 91 (85 to 94) | 58 (42 to 73) | 42 (28 to 58) |
| 11 months post 2nd dose (NZ98/254) (N=177, 41, 46) | 85 (79 to 90) | 66 (49 to 80) | 43 (29 to 59) |
The hSBA Geometric Mean Titers (GMTs) against the three strains of N. meningitidis serogroup B, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported.
| Titers | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Baseline H44/76 | 11 (8.74 to 14) | 11 (6.59 to 18) | 9.42 (5.73 to 15) |
| 1 month post 2nd dose (H44/76) (N=189, 45, 48) | 229 (192 to 274) | 11 (7.92 to 16) | 10 (7.18 to 15) |
| 3 months post 2nd dose (H44/76) (N=173, 40, 46) | 144 (116 to 178) | 9.07 (5.79 to 14) | 11 (7.07 to 16) |
| 5 months post 2nd dose (H44/76) (N=169, 43, 45) | 111 (89 to 138) | 12 (7.57 to 18) | 12 (7.62 to 18) |
| 11 months post 2nd dose (H44/76) (N=177, 40, 46) | 68 (54 to 84) | 14 (8.84 to 22) | 14 (8.97 to 21) |
| Baseline 5/99 | 6.44 (5.1 to 8.13) | 3.12 (1.97 to 4.95) | 5.49 (3.47 to 8.67) |
| 1 month post 2nd dose (5/99) (N=189, 45, 48) | 424 (355 to 507) | 2.63 (1.83 to 3.79) | 5.62 (3.95 to 8.01) |
| 3 months post 2nd dose (5/99) (N=173, 40, 46) | 169 (139 to 207) | 2.95 (1.94 to 4.47) | 5.6 (3.8 to 8.26) |
| 5 months post 2nd dose (5/99) (N=169, 43, 45) | 105 (87 to 128) | 3.36 (2.27 to 4.97) | 5.32 (3.63 to 7.79) |
| 11 months post 2nd dose (5/99) (N=177, 41, 46) | 55 (45 to 67) | 3.58 (2.37 to 5.4) | 5.98 (4.05 to 8.82) |
| Baseline NZ98/254 | 6.15 (4.82 to 7.84) | 4.32 (2.66 to 7) | 4.16 (2.58 to 6.72) |
| 1 month post 2nd dose (NZ98/254) (N=188, 45, 48) | 99 (80 to 122) | 4.82 (3.11 to 7.47) | 3.88 (2.54 to 5.93) |
| 3 months post 2nd dose (NZ98/254) (N=172, 40, 46) | 56 (44 to 73) | 4.93 (2.89 to 8.4) | 4.72 (2.87 to 7.76) |
| 5 months post 2nd dose (NZ98/254) (N=169, 43, 45) | 50 (38 to 66) | 6.5 (3.73 to 11) | 4.67 (2.72 to 8.03) |
| 11 months post 2nd dose (NZ98/254) (N=176, 41, 44) | 34 (26 to 45) | 7.77 (4.38 to 14) | 6.93 (3.99 to 12) |
The percentages of subjects with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. As serogroup A and W strains were not detected in substantial proportion of subjects during pharyngeal carriage analysis, these serogroups were not tested.
| Percentages of subjects | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Baseline Men C (N= 49, 194,50) | 90 (78 to 97) | 87 (81 to 91) | 80 (66 to 90) |
| 1 month post 2nd dose (Men C) (N=48, 182, 48) | 98 (89 to 100) | 99 (96 to 100) | 88 (75 to 95) |
| 11 months post 2nd dose (Men C) (N=48, 158, 41) | 94 (83 to 99) | 97 (93 to 99) | 88 (74 to 96) |
| Baseline Men Y | 72 (65 to 78) | 78 (72 to 84) | 78 (71 to 83) |
| 1 month post 2nd dose (Men Y) (N=187, 182, 188) | 81 (74 to 86) | 95 (90 to 97) | 82 (76 to 88) |
| 3 months post 2nd dose (Men Y) (N=173,164,175) | 79 (72 to 85) | 95 (90 to 97) | 82 (75 to 87) |
| 5 months post 2nd dose (Men Y) (N=170, 165, 170) | 78 (71 to 84) | 92 (87 to 96) | 84 (77 to 89) |
| 11 months post 2nd dose (Men Y) (N=177, 158, 165) | 77 (71 to 83) | 91 (86 to 95) | 81 (74 to 87) |
The hSBA antibody titers against N. meningitidis serogroups C and Y after rMenB+OMV NZ or MenACWY-CRM vaccination at different time points of the study as compared to the control group, are reported as GMTs. Serogroups A and W were not analysed.
| Titers | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Baseline Men C (N=49, 194, 50) | 43 (26 to 70) | 50 (39 to 65) | 32 (20 to 53) |
| 1 month post 2nd dose (Men C) (N=48, 182, 48) | 83 (55 to 126) | 1302 (1050 to 1615) | 37 (24 to 56) |
| 11 months post 2nd dose (MenC) (N=48, 158, 41) | 59 (38 to 91) | 438 (343 to 560) | 41 (25 to 66) |
| Baseline Men Y | 18 (14 to 22) | 19 (15 to 23) | 19 (15 to 23) |
| 1 month post 2nd dose (Men Y) (N=187, 182, 188) | 26 (21 to 32) | 83 (67 to 103) | 23 (18 to 28) |
| 3 months post 2nd dose (Men Y) (N=173, 164, 175) | 24 (19 to 30) | 69 (56 to 86) | 22 (17 to 27) |
| 5 months post 2nd dose (Men Y (N=170, 165, 170) | 23 (19 to 29) | 63 (51 to 78) | 22 (18 to 28) |
| 11 months post 2nd dose (Men Y) (N=177, 158, 165) | 21 (17 to 26) | 49 (39 to 61) | 22 (17 to 27) |
The percentages of subjects with hSBA seroresponse against N. meningitidis serogroups C and Y, after rMenB+OMV NZ or MenACWY-CRM vaccination as compared to the control group are reported. Seroresponse to N. meningitidis serogroups Cand Y is defined as :(1)for subjects with a pre-vaccination hSBA titer \< 1:4 to a post-vaccination hSBA titer ≥ 1:8 or (2) for subjects with a pre-vaccination hSBA titer ≥ 1:4, an increase in hSBA titer of at least four times the pre-vaccination titer. Analysis was not done for serogroups A and W.
| Percentages of subjects | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| 1 month post 2nd dose from day 1(Men C)N=48,181,48 | 8 (2 to 20) | 81 (75 to 87) | 4 (1 to 14) |
| 1 month post 2nd dose from day 1(Men Y) | 12 (8 to 17) | 44 (37 to 52) | 7 (4 to 12) |
The hSBA geometric mean titers against the N. meningitidis serogroups C and Y in subjects (who have received a prior dose of MenC vaccine) after MenACWY-CRM vaccination at different time points of the study as compared to the control group are reported. Analysis was not done for serogroups A and W.
| Titers | MenACWY | Control |
|---|---|---|
| Baseline (Men C) (N=46, 6) | 91 (51 to 160) | 157 (33 to 756) |
| 1 month post 2nd vaccination (Men C) (N=45, 6) | 1905 (1305 to 2779) | 154 (55 to 434) |
| 11 months post 2nd vaccination (Men C) (N=45, 6) | 691 (464 to 1028) | 125 (42 to 371) |
| Baseline (Men Y) | 21 (13 to 32) | 23 (13 to 41) |
| 1 month post 2nd vaccination (Men Y) (N=45, 26) | 89 (55 to 142) | 19 (10 to 36) |
| 3 months post 2nd vaccination (Men Y) (N=42, 25) | 67 (41 to 110) | 20 (11 to 38) |
| 5 months post 2nd vaccination (Men Y) (N=45, 26) | 65 (41 to 103) | 20 (11 to 37) |
| 11 months post 2nd vaccination (Men Y) (N=45, 26) | 48 (31 to 76) | 22 (12 to 39) |
The percentages of subjects (who have received a prior dose of MenC vaccine) with hSBA titers ≥1:8 against N. meningitidis serogroups C and Y after receiving MenACWY-CRM vaccination in this study as compared to the control group are reported. Analysis was not done for serogroups A and W.
| Percentages of subjects | MenACWY | Control |
|---|---|---|
| Baseline (Men C) (N=46,6) | 93 (82 to 99) | 100 (54 to 100) |
| 1 month post 2nd vaccination (Men C) (N=45, 6) | 100 (92 to 100) | 100 (54 to 100) |
| 11 months post 2nd vaccination (Men C) (N=45, 6) | 100 (92 to 100) | 100 (54 to 100) |
| Baseline (Men Y) | 80 (66 to 91) | 81 (61 to 93) |
| 1 month post 2nd vaccination (Men Y) (N=45, 26) | 96 (85 to 99) | 77 (56 to 91) |
| 3 months post 2nd vaccination (Men Y) (N=42, 25) | 95 (84 to 99) | 80 (59 to 93) |
| 5 months post 2nd vaccination (Men Y) (N=45, 26) | 96 (85 to 99) | 77 (56 to 91) |
| 11 months post 2nd vaccination (Men Y) (N=45, 26) | 91 (79 to 98) | 77 (56 to 91) |
The safety and tolerability of two doses of rMenB+OMV NZ vaccine (Group rMenB+OMV) and one dose of MenACWY-CRM vaccine (Group MenACWY) was assessed in terms of number of subjects with solicited local and systemic adverse events and other adverse events, following vaccination and compared to that of the control group.
| number of subjects | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Any local | 184 | 158 | 139 |
| Injection site pain (N=190, 186,191) | 181 | 143 | 117 |
| Injection site erythema (N=190, 186, 191) | 100 | 71 | 61 |
| Injection site induration (N=190, 186, 191) | 68 | 41 | 21 |
| Injection site swelling (N=190, 186, 191) | 68 | 31 | 23 |
| Any systemic | 169 | 133 | 140 |
| Arthralgia (N=190, 186, 191) | 38 | 27 | 29 |
| Nausea (N=190, 186, 191) | 36 | 23 | 24 |
| Malaise (N=190, 186, 191) | 57 | 41 | 46 |
| Myalgia (N=190, 186, 191) | 155 | 117 | 112 |
| Headache (N=190, 186, 191) | 71 | 56 | 75 |
| Rash (N=190, 186, 191) | 9 | 9 | 12 |
| Fever (≥38°C) (N= 190, 186,191) | 7 | 5 | 7 |
| Any Other | 64 | 22 | 25 |
| Temperature (≥40°C) (N= 190, 186, 191) | 0 | 0 | 0 |
| Antipyretic preventive med. used (N=190, 186, 191) | 20 | 7 | 3 |
| Antipyretic treatment med. used (N=190, 186, 191) | 55 | 17 | 22 |
Collected over Solicited adverse events were collected from Day1 to day 7 post vaccination; unsolicited AEs were collected throughout the study period (Day 1-Day 361). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB+OMV | — | 31/974 (3.2%) | 200/974 (20.5%) |
| MenACWY | — | 26/984 (2.6%) | 186/984 (18.9%) |
| Control | — | 20/985 (2%) | 172/985 (17.5%) |
| Event | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| PyelonephritisInfections and infestations | 3/974 | 0/984 | 0/985 |
| Abdominal painGastrointestinal disorders | 1/974 | 3/984 | 0/985 |
| AppendicitisInfections and infestations | 1/974 | 3/984 | 1/985 |
| TonsillitisInfections and infestations | 2/974 | 0/984 | 0/985 |
| Urinary tract infectionInfections and infestations | 2/974 | 0/984 | 0/985 |
| Pilonidal cystInfections and infestations | 0/974 | 2/984 | 0/985 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/974 | 2/984 | 0/985 |
| Thyroiditis acuteEndocrine disorders | 1/974 | 0/984 | 0/985 |
| Edema peripheralGeneral disorders | 1/974 | 0/984 | 0/985 |
| Anaphylactic reactionImmune system disorders | 1/974 | 1/984 | 0/985 |
| Event | rMenB+OMV | MenACWY | Control |
|---|---|---|---|
| Injection site painGeneral disorders | 182/974 | 145/984 | 117/985 |
| MyalgiaMusculoskeletal and connective tissue disorders | 155/974 | 119/984 | 112/985 |
| Injection site erythemaGeneral disorders | 102/974 | 71/984 | 61/985 |
| HeadacheNervous system disorders | 82/974 | 67/984 | 85/985 |
| Injection site indurationGeneral disorders | 68/974 | 42/984 | 21/985 |
| Injection site swellingGeneral disorders | 68/974 | 32/984 | 23/985 |
| MalaiseGeneral disorders | 58/974 | 43/984 | 47/985 |
| Age, Continuous(years) | rMenB+OMV | MenACWY | Control | Total |
|---|---|---|---|---|
| Mean | 19.9 ± 1.6 | 19.9 ± 1.6 | 19.8 ± 1.6 | 19.9 ± 1.6 |
| Sex: Female, Male(Participants) | rMenB+OMV | MenACWY | Control | Total |
|---|---|---|---|---|
| Female | 516 | 533 | 547 | 1596 |
| Male | 463 | 455 | 440 | 1358 |
The record gives a start of Sep 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2014, 2 years after primary completion. A results delay was requested in Dec 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.